MINDEN, Nev. - July 10, 2012 (Investorideas.com Newswire) Small cap tech stock news update:
Spare Backup Inc.(OTCBB: SPBU), a provider of data backup and security
software for smartphones, tablets and PCs, which is carrier and
manufacturer agnostic, reports it has reduced its outstanding
liabilities by approximately $1 million dollars in the third quarter of
2012 as management has begun an extensive review of certain accounts
payable and other obligations of the company. Management believes
there will be additional reductions in overall liabilities including the
elimination of certain aged payables and renegotiation of others which
will help to strengthen its balance sheet in the coming quarters.
"Our team is working diligently to place Spare Backup on more solid financial
ground as we support the extensive launch of our service in North
America and Europe." commented Cery Perle, CEO of Spare Backup, "Our
initial review in conjunction with legal counsel has led to the
elimination of approximately $1 million dollars in legacy items and we
are currently reviewing a number of additional items which we believe
will lead to a further reduction in liabilities. We are confident that
through these measures and through our aggressive rollout, we will be
able to achieve our growth targets and build a profitable future for our
company and its stockholders."
About Spare Backup, Inc.
Spare Backup, Inc. is a leading provider of data backup and
security software for smartphones, tablets and PCs. Spare Backup's
software enables consumers and small to medium sized businesses to
easily protect valuable computer and mobile data quickly, automatically
and cost-effectively. Spare Backup software intelligently selects,
secures and stores personal and business content on a continuous basis
or according to the schedule of the user's choice. It also allows for
the integration of that content across various devices and provides
enhanced security features to protect valuable data on any lost or
stolen devices. Spare Backup software is the first totally automated
cloud-based backup service that is distributed on a stand-alone or
private label basis through major retail and warranty service partners
in North America and Europe.
Safe Harbor Statement
The Private Securities Litigation Reform Act of 1995 provides a
safe harbor for forward-looking information made on the company's
behalf. All statements, other than statements of historical facts,
which address the company's expectations of sources of capital or which
express the company's expectation for the future with respect to
financial performance or operating strategies can be identified as
forward-looking statements. Such statements made by the company are
based on knowledge of the environment in which it operates, but because
of the possibility of unknown factors, as well as other factors beyond
the control of the company, actual results may differ materially from
the expectations expressed in the forward-looking statement. An
investment in our common stock involves a significant degree of risk.
You should not invest
in our common stock unless you can afford to lose your entire
investment. You should consider carefully all risk factors and other
information in our annual report and quarterly filings before deciding
to invest in our common stock. If any of the following risks and
uncertainties develops into actual events, our business, financial
condition or results of operations could be materially adversely
affected and you could lose your entire investment in our company.
Forward Looking Statements:
This press release contains forward-looking statements that involve
a number of risks and uncertainties, including statements regarding the
outlook of the Company's business and results of operations. By nature,
these risks and uncertainties could cause actual results to differ
materially from those indicated. Generally speaking, any statements
using terms such as "will," "expect," "anticipate," or "may," or which
otherwise predict or address future results or events, are likely to
contain forward-looking statements. It is important to note that actual
results may differ materially from what is indicated in any
forward-looking statement. Readers should consider any forward-looking
statements in light of factors that could cause actual results to vary.
These factors are described in Spare Backups filings with the SEC, and
readers should refer to those filings, including Risk Factors described
in those filings, in connection with any forward-looking statements.
The Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT
Investor Contact:
Kevin Fickle, President
NUWA Group, LLC
415.525.8275
kevin@nuwagroup.com
Published at Investorideas.com
Disclaimer/ Disclosure : The Investorideas.com is a third party
publisher of news and research Our sites do not make recommendations,
but offer information portals to research news, articles, stock lists
and recent research. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. This site
is currently compensated by featured companies, news submissions and
online advertising. Disclosure: A third party on behalf of SPBU
compensated Investorideas.com for news release publishing and
distribution: three thousand five hundred per month and four hundred
thousand 144 shares for a six month period
BC Residents and Investor Disclaimer: Effective September 15
2008 - all BC investors should review all OTC and Pink sheet listed
companies for adherence in new disclosure filings and filing appropriate
documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Tuesday, July 10, 2012
Spare Backup (OTCBB: SPBU), Provider of Data Backup and Security Software for smartphones, tablets and PCs, Reduces Liabilities by $1 Million for Third Quarter
MINDEN, Nev. - July 10, 2012 (Investorideas.com Newswire) Spare Backup Inc.(OTCBB: SPBU),
a provider of data backup and security software for smartphones,
tablets and PCs, which is carrier and manufacturer agnostic, today
announced that Spare Backup has reduced its outstanding liabilities by
approximately $1 million dollars
in the third quarter of 2012 as management has begun an extensive
review of certain accounts payable and other obligations of the company.
Management believes there will be additional reductions in overall
liabilities including the elimination of certain aged payables and
renegotiation of others which will help to strengthen its balance sheet
in the coming quarters.
"Our team is working diligently to place Spare Backup on more solid financial ground as we support the extensive launch of our service in North America and Europe." commented Cery Perle, CEO of Spare Backup, "Our initial review in conjunction with legal counsel has led to the elimination of approximately $1 million dollars in legacy items and we are currently reviewing a number of additional items which we believe will lead to a further reduction in liabilities. We are confident that through these measures and through our aggressive rollout, we will be able to achieve our growth targets and build a profitable future for our company and its stockholders."
About Spare Backup, Inc.
Spare Backup, Inc. is a leading provider of data backup and security software for smartphones, tablets and PCs. Spare Backup's software enables consumers and small to medium sized businesses to easily protect valuable computer and mobile data quickly, automatically and cost-effectively. Spare Backup software intelligently selects, secures and stores personal and business content on a continuous basis or according to the schedule of the user's choice. It also allows for the integration of that content across various devices and provides enhanced security features to protect valuable data on any lost or stolen devices. Spare Backup software is the first totally automated cloud-based backup service that is distributed on a stand-alone or private label basis through major retail and warranty service partners in North America and Europe.
Safe Harbor Statement
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking information made on the company's behalf. All statements, other than statements of historical facts, which address the company's expectations of sources of capital or which express the company's expectation for the future with respect to financial performance or operating strategies can be identified as forward-looking statements. Such statements made by the company are based on knowledge of the environment in which it operates, but because of the possibility of unknown factors, as well as other factors beyond the control of the company, actual results may differ materially from the expectations expressed in the forward-looking statement. An investment in our common stock involves a significant degree of risk. You should not invest in our common stock unless you can afford to lose your entire investment. You should consider carefully all risk factors and other information in our annual report and quarterly filings before deciding to invest in our common stock. If any of the following risks and uncertainties develops into actual events, our business, financial condition or results of operations could be materially adversely affected and you could lose your entire investment in our company.
Forward Looking Statements:
This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in Spare Backups filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT
Investor Contact:
Kevin Fickle, President
NUWA Group, LLC
415.525.8275
kevin@nuwagroup.com
Published at Investorideas.com
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SPBU compensated Investorideas.com for news release publishing and distribution: three thousand five hundred per month and four hundred thousand 144 shares for a six month period
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
"Our team is working diligently to place Spare Backup on more solid financial ground as we support the extensive launch of our service in North America and Europe." commented Cery Perle, CEO of Spare Backup, "Our initial review in conjunction with legal counsel has led to the elimination of approximately $1 million dollars in legacy items and we are currently reviewing a number of additional items which we believe will lead to a further reduction in liabilities. We are confident that through these measures and through our aggressive rollout, we will be able to achieve our growth targets and build a profitable future for our company and its stockholders."
About Spare Backup, Inc.
Spare Backup, Inc. is a leading provider of data backup and security software for smartphones, tablets and PCs. Spare Backup's software enables consumers and small to medium sized businesses to easily protect valuable computer and mobile data quickly, automatically and cost-effectively. Spare Backup software intelligently selects, secures and stores personal and business content on a continuous basis or according to the schedule of the user's choice. It also allows for the integration of that content across various devices and provides enhanced security features to protect valuable data on any lost or stolen devices. Spare Backup software is the first totally automated cloud-based backup service that is distributed on a stand-alone or private label basis through major retail and warranty service partners in North America and Europe.
Safe Harbor Statement
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking information made on the company's behalf. All statements, other than statements of historical facts, which address the company's expectations of sources of capital or which express the company's expectation for the future with respect to financial performance or operating strategies can be identified as forward-looking statements. Such statements made by the company are based on knowledge of the environment in which it operates, but because of the possibility of unknown factors, as well as other factors beyond the control of the company, actual results may differ materially from the expectations expressed in the forward-looking statement. An investment in our common stock involves a significant degree of risk. You should not invest in our common stock unless you can afford to lose your entire investment. You should consider carefully all risk factors and other information in our annual report and quarterly filings before deciding to invest in our common stock. If any of the following risks and uncertainties develops into actual events, our business, financial condition or results of operations could be materially adversely affected and you could lose your entire investment in our company.
Forward Looking Statements:
This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in Spare Backups filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT
Investor Contact:
Kevin Fickle, President
NUWA Group, LLC
415.525.8275
kevin@nuwagroup.com
Published at Investorideas.com
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SPBU compensated Investorideas.com for news release publishing and distribution: three thousand five hundred per month and four hundred thousand 144 shares for a six month period
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Monday, July 09, 2012
Tech Stock News Alert: Spare Backup (OTCBB:SPBU) Launches Spare Mobile Security and Backup Services with Second Financial Services Group in Europe
MINDEN, Nev. - July 9, 2012 (Investorideas.com Newswire) Tech stock news: Spare Backup Inc. (OTCBB: SPBU),
a provider of data backup and security software for smartphones,
tablets and PCs, which is carrier and manufacturer agnostic, today
announced that it plans to launch Spare's mobile security and data
backup services with a second financial services group in Europe as part
of the master services agreement with our largest European distribution
partner. Spare mobile services will be incorporated as part of various
insurance and warranty packages offered by the financial services
group.
The launch, which is expected to take place in the next 30 days, is part of Spare Backup's strategy of providing our services on a private label basis to providers of mobile warranty and insurance services. This second financial services launch is also a key milestone for Spare Backup as it helps validate that our software meets the stringent standards for encryption and security mandated by the financial services industry and can be readily deployed with other industry partners across the globe.
Initial data from our first launch in North America indicate a customer take rate of approximately 30% on offerings incorporating Spare Mobile services. Management anticipates similar results for other scheduled launches in Europe and North America as Spare Backup continues an aggressive deployment phase with its current partners.
"We are excited to launch our Spare Mobile offerings with a second financial services industry partner as we begin to see some early sales data that supports our efforts in the warranty and mobile insurance space," commented Cery Perle, CEO of Spare Backup. "Through our private labeled websites we can support multiple launches in a very quick time frame and we intend to diligently work with our partners in North America and other parts of the world to rapidly grow our customer base. We believe we are in the right place at the right time in the mobile space to quickly gain traction and support a very large recurring revenue base for our company to fuel our future growth."
About Spare Backup, Inc.
Spare Backup, Inc. is a leading provider of data backup and security software for smartphones, tablets and PCs. Spare Backup's software enables consumers and small to medium sized businesses to easily protect valuable computer and mobile data quickly, automatically and cost-effectively. Spare Backup software intelligently selects, secures and stores personal and business content on a continuous basis or according to the schedule of the user's choice. It also allows for the integration of that content across various devices and provides enhanced security features to protect valuable data on any lost or stolen devices. Spare Backup software is the first totally automated cloud-based backup service that is distributed on a stand-alone or private label basis through major retail and warranty service partners in North America and Europe.
Safe Harbor Statement
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking information made on the company's behalf. All statements, other than statements of historical facts, which address the company's expectations of sources of capital or which express the company's expectation for the future with respect to financial performance or operating strategies can be identified as forward-looking statements. Such statements made by the company are based on knowledge of the environment in which it operates, but because of the possibility of unknown factors, as well as other factors beyond the control of the company, actual results may differ materially from the expectations expressed in the forward-looking statement. An investment in our common stock involves a significant degree of risk. You should not invest in our common stock unless you can afford to lose your entire investment. You should consider carefully all risk factors and other information in our annual report and quarterly filings before deciding to invest in our common stock. If any of the following risks and uncertainties develops into actual events, our business, financial condition or results of operations could be materially adversely affected and you could lose your entire investment in our company.
Forward Looking Statements:
This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in Spare Backups filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT
Investor Contact:
Kevin Fickle, President
NUWA Group, LLC
415.525.8275
kevin@nuwagroup.com
Published at Investorideas.com
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SPBU compensated Investorideas.com for news release publishing and distribution: three thousand five hundred per month and four hundred thousand 144 shares for a six month period
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
The launch, which is expected to take place in the next 30 days, is part of Spare Backup's strategy of providing our services on a private label basis to providers of mobile warranty and insurance services. This second financial services launch is also a key milestone for Spare Backup as it helps validate that our software meets the stringent standards for encryption and security mandated by the financial services industry and can be readily deployed with other industry partners across the globe.
Initial data from our first launch in North America indicate a customer take rate of approximately 30% on offerings incorporating Spare Mobile services. Management anticipates similar results for other scheduled launches in Europe and North America as Spare Backup continues an aggressive deployment phase with its current partners.
"We are excited to launch our Spare Mobile offerings with a second financial services industry partner as we begin to see some early sales data that supports our efforts in the warranty and mobile insurance space," commented Cery Perle, CEO of Spare Backup. "Through our private labeled websites we can support multiple launches in a very quick time frame and we intend to diligently work with our partners in North America and other parts of the world to rapidly grow our customer base. We believe we are in the right place at the right time in the mobile space to quickly gain traction and support a very large recurring revenue base for our company to fuel our future growth."
About Spare Backup, Inc.
Spare Backup, Inc. is a leading provider of data backup and security software for smartphones, tablets and PCs. Spare Backup's software enables consumers and small to medium sized businesses to easily protect valuable computer and mobile data quickly, automatically and cost-effectively. Spare Backup software intelligently selects, secures and stores personal and business content on a continuous basis or according to the schedule of the user's choice. It also allows for the integration of that content across various devices and provides enhanced security features to protect valuable data on any lost or stolen devices. Spare Backup software is the first totally automated cloud-based backup service that is distributed on a stand-alone or private label basis through major retail and warranty service partners in North America and Europe.
Safe Harbor Statement
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking information made on the company's behalf. All statements, other than statements of historical facts, which address the company's expectations of sources of capital or which express the company's expectation for the future with respect to financial performance or operating strategies can be identified as forward-looking statements. Such statements made by the company are based on knowledge of the environment in which it operates, but because of the possibility of unknown factors, as well as other factors beyond the control of the company, actual results may differ materially from the expectations expressed in the forward-looking statement. An investment in our common stock involves a significant degree of risk. You should not invest in our common stock unless you can afford to lose your entire investment. You should consider carefully all risk factors and other information in our annual report and quarterly filings before deciding to invest in our common stock. If any of the following risks and uncertainties develops into actual events, our business, financial condition or results of operations could be materially adversely affected and you could lose your entire investment in our company.
Forward Looking Statements:
This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in Spare Backups filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT
Investor Contact:
Kevin Fickle, President
NUWA Group, LLC
415.525.8275
kevin@nuwagroup.com
Published at Investorideas.com
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SPBU compensated Investorideas.com for news release publishing and distribution: three thousand five hundred per month and four hundred thousand 144 shares for a six month period
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Medical Technology and Biotech Stock Alert; Kallo (OTCBB: KALO) Trades up 30%
New York, NY - July 9, 2012 (Investorideas.com Newswire) Investor Ideas, www.InvestorIdeas.com,
a global investor research portal for independent investors, issues a
trading alert for medical technology stock, Kallo, Inc. (OTCBB: KALO), currently trading at $0.1310, up $ 0.0310 (31.00%) with a high of $0.1450, 0.0450(45.00%) on relatively light volume.
On June 29 th the Company issued news that it is licensed to distribute their Electronic Medical Record (EMR) systems, Picture Archiving and Communication System (PACS), and Medical Device Connectivity System (MDC) throughout The United States and Canada.
ohn Cecil, Chairman and CEO noted in the press release, "The United States and Canada are responsible for approximately 50% of the global IT expenditures in the healthcare sector. We are positioned to increase our presence and distribution in the marketplace."
ABOUT Kallo, Inc.
Kallo, Inc., a medical information company, engages in the manufacturing and development of software that assists physicians and nurses to streamline patient information. Its software solution includes Electronic Medical Record software (EMR) and connectivity software that gathers medical information from various sources and deposits it into a single source as an electronic medical record for each patient.
About Investorideas.com
InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp Disclosure: Compensation: Kallo Inc. (OTCBB: KALO) three thousand five hundred and 200,000 144 shares by a third party for news publishing, syndication, email distribution
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
On June 29 th the Company issued news that it is licensed to distribute their Electronic Medical Record (EMR) systems, Picture Archiving and Communication System (PACS), and Medical Device Connectivity System (MDC) throughout The United States and Canada.
ohn Cecil, Chairman and CEO noted in the press release, "The United States and Canada are responsible for approximately 50% of the global IT expenditures in the healthcare sector. We are positioned to increase our presence and distribution in the marketplace."
ABOUT Kallo, Inc. Kallo, Inc., a medical information company, engages in the manufacturing and development of software that assists physicians and nurses to streamline patient information. Its software solution includes Electronic Medical Record software (EMR) and connectivity software that gathers medical information from various sources and deposits it into a single source as an electronic medical record for each patient.
About Investorideas.com
InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp Disclosure: Compensation: Kallo Inc. (OTCBB: KALO) three thousand five hundred and 200,000 144 shares by a third party for news publishing, syndication, email distribution
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Gold and Mining Stocks; Preliminary Results from the Deep Hole Program Confirms Extension of Gold Mineralization 800 Metres Down Plunge and 900 Metres Vertical Depth - Gold Bullion Development Corp. (TSX-V: GBB)
VANCOUVER - July 9, 2012 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (TSXV: GBB, OTC PINK: GBBFF)
(the "Company" or "Gold Bullion") is pleased to announce preliminary
drill results from holes and wedge holes located to the north of the
existing mineralized area of the Granada Gold Property. The subject
property is located along the prolific Cadillac trend in North-western
Quebec, 5 km south of the city of Rouyn-Noranda.
Frank Basa, Gold Bullion's CEO, is very encouraged by results that consistently demonstrate the presence of widespread significant gold on the Granada property. Hole DUP-12-02 intercepted 4.15 grams Au per tonne over a 3 metre core length at 615 metres and 4.58 grams per tonne Au over 3 metres at 995 metres depth.
The drill plan initially called for three deep holes with one wedge in each hole and commenced with hole DUP-12-03. Due to excessive deviation, this hole was subsequently abandoned at the 400-metre level. Hole DUP-12-03A, located 400 metres NNE (12 degrees North) of hole GR-11-390 was drilled just 25 metres to the west of DUP-12-03 and down to a depth of 1,323 metres. Three wedge holes W1, W2 and W3 were put into DUP-12-03A.
Hole DUP-12-02, located 830 metres NNE (24 degrees North) of hole GR-11-390, was drilled down to 1,593 metres with one wedge hole added, W1.
Due to the success of DUP-12-03A, DUP-12-02 and the associated wedges, (observation of visible gold and typical alteration zones) and in conjunction with the observation of visible gold in the western extension holes GR-11-375 and GR-11-363 in the backlog program, the drill was reassigned to the western extension to further evaluate near surface mineralization and hole DUP-12-01 drilling was temporarily put on hold.
The following table contains the highlights of the preliminary results. These additional gold fire assay results continue to demonstrate low grade, high tonnage, near surface intersections while also confirming specific high-grade zones at depth with thickness and grade suitable for underground mining.
Core length close to true thickness
Blanks and standards were inserted into the sequence at the QA/QC Laboratory while the 50-gram fire assay results were provided by Accurassay Laboratory prepared in Rouyn. Fire assays were conducted at their facility in Ontario.
Frank Basa, Gold Bullion's CEO, is pleased as results continue to demonstrate the presence of widespread significant gold on the Granada property in support of the hypothesis encompassing both a low grade near surface mine and a higher grade underground mine.
Claude Duplessis, Eng. is acting as the qualified person (QP) for Gold Bullion Development Corp. in compliance with National Instrument 43-101 and has reviewed the technical contents of this press release.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Qu�bec. Additional information on the company's Granada gold property is available by visiting their website at www.GoldBullionDevelopmentCorp.com and on SEDAR.com.
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Frank Basa, Gold Bullion's CEO, is very encouraged by results that consistently demonstrate the presence of widespread significant gold on the Granada property. Hole DUP-12-02 intercepted 4.15 grams Au per tonne over a 3 metre core length at 615 metres and 4.58 grams per tonne Au over 3 metres at 995 metres depth.
The drill plan initially called for three deep holes with one wedge in each hole and commenced with hole DUP-12-03. Due to excessive deviation, this hole was subsequently abandoned at the 400-metre level. Hole DUP-12-03A, located 400 metres NNE (12 degrees North) of hole GR-11-390 was drilled just 25 metres to the west of DUP-12-03 and down to a depth of 1,323 metres. Three wedge holes W1, W2 and W3 were put into DUP-12-03A.
Hole DUP-12-02, located 830 metres NNE (24 degrees North) of hole GR-11-390, was drilled down to 1,593 metres with one wedge hole added, W1.
Due to the success of DUP-12-03A, DUP-12-02 and the associated wedges, (observation of visible gold and typical alteration zones) and in conjunction with the observation of visible gold in the western extension holes GR-11-375 and GR-11-363 in the backlog program, the drill was reassigned to the western extension to further evaluate near surface mineralization and hole DUP-12-01 drilling was temporarily put on hold.
The following table contains the highlights of the preliminary results. These additional gold fire assay results continue to demonstrate low grade, high tonnage, near surface intersections while also confirming specific high-grade zones at depth with thickness and grade suitable for underground mining.
Core length close to true thicknessBlanks and standards were inserted into the sequence at the QA/QC Laboratory while the 50-gram fire assay results were provided by Accurassay Laboratory prepared in Rouyn. Fire assays were conducted at their facility in Ontario.
Frank Basa, Gold Bullion's CEO, is pleased as results continue to demonstrate the presence of widespread significant gold on the Granada property in support of the hypothesis encompassing both a low grade near surface mine and a higher grade underground mine.
Claude Duplessis, Eng. is acting as the qualified person (QP) for Gold Bullion Development Corp. in compliance with National Instrument 43-101 and has reviewed the technical contents of this press release.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Qu�bec. Additional information on the company's Granada gold property is available by visiting their website at www.GoldBullionDevelopmentCorp.com and on SEDAR.com.
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Disclosure, Disclaimer/ Investorideas.com
is paid by GBB to publish news and distribute content through
Investordeas.com Newswire and its syndicated partners and blogs (five
hundred per month)Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Biotech and Pharma Stock Investor News; Sunshine Biopharma (OTCBB: SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY); Targeting Aggressive Forms of Cancer
New York, New York - July 9, 2012 - Investorideas.com, an investor
research portal specializing in sector research including biotech and
pharma stocks, issues a report on biotech companies targeting aggressive
forms of cancer; Roche's (SIX: RO, ROG; OTCQX: RHHBY) Herceptin® cancer drug and Sunshine Biopharma Inc. (OTCBB: SBFM) with its lead compound, Adva-27a.
Roche is the largest biotech company in the world and Sunshine Biopharma is a small microcap biopharma company. The two genes associated with aggressive forms of cancer are Her2 and Top2; Roche is targeting Her2-Positive patients and Sunshine Biopharma is targeting multidrug resistant Top2, which has no current effective drugs in the market for patients.
Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) recently noted in an interview with Investorideas.com “Herceptin® is an excellent drug and is very effective in treating Her2-Positive breast cancer patients. However, only about 25% of the breast cancer patients are Her2-Positive. For the remaining 75%, Herceptin® does not work. This is where our Adva-27a comes in.”
Sunshine Biopharma reported on July 11, 2011 that Adva-27a had shown 16-fold more effectiveness against MCF-7/MDR Multidrug Resistant Breast Cancer and announced on June 26 th results that Adva-27a is significantly more effective at killing Multidrug Resistant Small-Cell Lung Cancer cells than Etoposide, the current commonly used drug for this type of cancer.
Adva-27a was designed and synthesized de novo in 2006. Patents covering Adva-27a and derivatives have recently issued in the United States and Europe and are pending in other countries around the world. Sunshine Biopharma has announced collaborations with the State University of New York at Binghamton and McGill University's Jewish General Hospital in Montreal (Canada) focused on the development of Adva-27a through clinical trials.
Herceptin® was developed originally by Genentech, starting with research that dated back to the 1970's and Roche later signed a licensing agreement in 1998 for exclusive marketing rights for Herceptin outside of the United States. A few months later Herceptin received FDA approval for use in women with breast cancer that overexpresses the HER2 protein. Herceptin® was the first therapeutic antibody targeted to a specific (HER2) cancer-related molecular marker to receive FDA approval. Roche purchased Genentech in March 2009 for approximately $46.8 billion.
The most recent development on Herceptin® was June this year when Roche announced the FDA had approved Perjeta® (pertuzumab) in combination with Herceptin® and docetaxel chemotherapy for the treatment of people with Her2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Herceptin® sales were over $5 billion in 2010 but Herceptin® begins to lose patent protection in world markets in 2014.
Herceptin® Worldwide Sales in 2009/10
Source: http://www.evaluatepharma.com/
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About Roche (SIX: RO, ROG; OTCQX: RHHBY):
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
www.roche.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Roche is the largest biotech company in the world and Sunshine Biopharma is a small microcap biopharma company. The two genes associated with aggressive forms of cancer are Her2 and Top2; Roche is targeting Her2-Positive patients and Sunshine Biopharma is targeting multidrug resistant Top2, which has no current effective drugs in the market for patients.
Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) recently noted in an interview with Investorideas.com “Herceptin® is an excellent drug and is very effective in treating Her2-Positive breast cancer patients. However, only about 25% of the breast cancer patients are Her2-Positive. For the remaining 75%, Herceptin® does not work. This is where our Adva-27a comes in.”
Sunshine Biopharma reported on July 11, 2011 that Adva-27a had shown 16-fold more effectiveness against MCF-7/MDR Multidrug Resistant Breast Cancer and announced on June 26 th results that Adva-27a is significantly more effective at killing Multidrug Resistant Small-Cell Lung Cancer cells than Etoposide, the current commonly used drug for this type of cancer.
Adva-27a was designed and synthesized de novo in 2006. Patents covering Adva-27a and derivatives have recently issued in the United States and Europe and are pending in other countries around the world. Sunshine Biopharma has announced collaborations with the State University of New York at Binghamton and McGill University's Jewish General Hospital in Montreal (Canada) focused on the development of Adva-27a through clinical trials.
Herceptin® was developed originally by Genentech, starting with research that dated back to the 1970's and Roche later signed a licensing agreement in 1998 for exclusive marketing rights for Herceptin outside of the United States. A few months later Herceptin received FDA approval for use in women with breast cancer that overexpresses the HER2 protein. Herceptin® was the first therapeutic antibody targeted to a specific (HER2) cancer-related molecular marker to receive FDA approval. Roche purchased Genentech in March 2009 for approximately $46.8 billion.
The most recent development on Herceptin® was June this year when Roche announced the FDA had approved Perjeta® (pertuzumab) in combination with Herceptin® and docetaxel chemotherapy for the treatment of people with Her2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Herceptin® sales were over $5 billion in 2010 but Herceptin® begins to lose patent protection in world markets in 2014.
Herceptin® Worldwide Sales in 2009/10
Source: http://www.evaluatepharma.com/About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About Roche (SIX: RO, ROG; OTCQX: RHHBY):
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
www.roche.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Published at Investorideas.com newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): ProfileDisclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Friday, July 06, 2012
Tech Stock Investor News Alert; Xyratex (NasdaqGS: XRTX) Moves on Second Quarter Results
New York, NY - July 6, 2012 (InvestorIdeas.com Newswire) Investor Ideas, www.InvestorIdeas.com,
a global investor research portal for independent investors, issues a
tech stock trading alert for data storage technology provider, Xyratex
Ltd. (NasdaqGS :XRTX), trading at $13.20, gaining $1.48 or (12.63%) in
morning trading. The stock, one of NASDAQ’s top percentage gainers,
moved on results for the second fiscal quarter ended May 31, 2012.
Revenues for the second quarter were $322.1 million, a decrease of 4.9% compared to revenues of $338.5 million for the same period last year.
For the second quarter, GAAP net income was $7.0 million, or $0.24 per diluted share, compared to GAAP net loss of $4.6 million, or $0.15 per share, in the same period last year. Non-GAAP net income was $9.3 million, or $0.32 per diluted share, compared to non-GAAP net loss of $1.9 million, or $0.06 per share, in the same quarter a year ago(1).
Gross profit margin in the second quarter was 16.5%, compared to 12.9% in the same period last year and 17.9% in the prior quarter. The increase from last year primarily reflects improved gross margins for HDD Capital Equipment products, which had been impacted by significantly reduced revenue and specific inventory provisions in the prior year.
About Xyratex
Xyratex is a leading provider of data storage technology, including modular solutions for the enterprise data storage industry, and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex enterprise data storage platforms provide a range of advanced, scalable data storage solutions for the Original Equipment Manufacturer and High Performance Computing communities. As the largest capital equipment supplier to the HDD industry, Xyratex enables disk drive manufacturers and their component suppliers to meet today's technology and productivity requirements. Xyratex has over 25 years of experience in research and development relating to disk drives, storage systems and manufacturing process technology.
Founded in 1994 in an MBO from IBM, and with headquarters in the UK, Xyratex has an established global base with R&D and operational facilities in North America, Asia and Europe.
About Investorideas.com
InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Revenues for the second quarter were $322.1 million, a decrease of 4.9% compared to revenues of $338.5 million for the same period last year.
For the second quarter, GAAP net income was $7.0 million, or $0.24 per diluted share, compared to GAAP net loss of $4.6 million, or $0.15 per share, in the same period last year. Non-GAAP net income was $9.3 million, or $0.32 per diluted share, compared to non-GAAP net loss of $1.9 million, or $0.06 per share, in the same quarter a year ago(1).
Gross profit margin in the second quarter was 16.5%, compared to 12.9% in the same period last year and 17.9% in the prior quarter. The increase from last year primarily reflects improved gross margins for HDD Capital Equipment products, which had been impacted by significantly reduced revenue and specific inventory provisions in the prior year.
About XyratexXyratex is a leading provider of data storage technology, including modular solutions for the enterprise data storage industry, and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex enterprise data storage platforms provide a range of advanced, scalable data storage solutions for the Original Equipment Manufacturer and High Performance Computing communities. As the largest capital equipment supplier to the HDD industry, Xyratex enables disk drive manufacturers and their component suppliers to meet today's technology and productivity requirements. Xyratex has over 25 years of experience in research and development relating to disk drives, storage systems and manufacturing process technology.
Founded in 1994 in an MBO from IBM, and with headquarters in the UK, Xyratex has an established global base with R&D and operational facilities in North America, Asia and Europe.
About Investorideas.com
InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
NASDAQ Morning Stock Leader: LaCrosse Footwear (NasdaqGM: BOOT) Leaps 80% on Acqusiiton News
New York, NY - July 6, 2012 (Investorideas.com Newswire)
Investorideas.com, a leader in sector research for independent investors
issues a trading alert for NASDAQ top percentage gainer this morning,
Lacrosse Footwear Inc. (NasdaqGM : BOOT) gapping up and trading at
$19.88, gaining $ 8.90 or (81.06%) 10:30AM EDT on over 1.4 Million
shares following acquisition news.
ABC-MART, INC. (TSE:2670), Japan's leading retailer of athletic, business and casual footwear, reported it has entered into an agreement with LaCrosse Footwear, Inc. (BOOT), whereby ABC-MART will acquire all outstanding shares of LaCrosse Footwear stock for $20 per share in cash, or approximately $138 million.
About LaCrosse Footwear, Inc. (NasdaqGM: BOOT)
LaCrosse Footwear, Inc. is a leading developer and marketer of branded, premium and innovative footwear for work and outdoor users. The Company's trusted Danner® and LaCrosse® brands are sold to a network of specialty retailers and distributors in the United States, Canada, Europe and Asia. Work consumers include people in law enforcement, transportation, mining, oil and gas exploration and extraction, construction, military services and other occupations that require high-performance and protective footwear as a critical tool for the job. Outdoor consumers include people active in hunting, hiking and other outdoor recreational activities.
websites at http://www.lacrossefootwear.com and http://www.danner.com. For additional corporate information, see our corporate website at www.lacrossefootwearinc.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech, defense and security stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get Free investor news and stock alerts at Investor Ideas
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
ABC-MART, INC. (TSE:2670), Japan's leading retailer of athletic, business and casual footwear, reported it has entered into an agreement with LaCrosse Footwear, Inc. (BOOT), whereby ABC-MART will acquire all outstanding shares of LaCrosse Footwear stock for $20 per share in cash, or approximately $138 million.
About LaCrosse Footwear, Inc. (NasdaqGM: BOOT) LaCrosse Footwear, Inc. is a leading developer and marketer of branded, premium and innovative footwear for work and outdoor users. The Company's trusted Danner® and LaCrosse® brands are sold to a network of specialty retailers and distributors in the United States, Canada, Europe and Asia. Work consumers include people in law enforcement, transportation, mining, oil and gas exploration and extraction, construction, military services and other occupations that require high-performance and protective footwear as a critical tool for the job. Outdoor consumers include people active in hunting, hiking and other outdoor recreational activities.
websites at http://www.lacrossefootwear.com and http://www.danner.com. For additional corporate information, see our corporate website at www.lacrossefootwearinc.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech, defense and security stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get Free investor news and stock alerts at Investor Ideas
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Thursday, July 05, 2012
Biotech Investor Trading Alert: Sunshine Biopharma (OTCBB: SBFM) Trades up 28%
New York, New York - July 5, 2012 (Investorideas.com Newswire,
Biotechindustrystocks.com) Investorideas.com, an investor research
portal specializing in sector research including biotech and pharma
stocks, issues a trading alert for Sunshine Biopharma Inc. (OTCBB: SBFM). The stock is trading at $0.41, up $ 0.09 or (28.13%) on 247,000 shares.
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
Last week the Company reported that it had completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results of the study showed that Adva-27a is significantly more effective at killing Multidrug Resistant Small Cell Lung Cancer cells than Etoposide, the current commonly used drug for this type of cancer. This is the second form of Multidrug Resistant Cancer that Adva-27a has shown effectiveness against. The first, which we had announced on July 11, 2011, was MCF-7/MDR Multidrug Resistant Breast Cancer.
Recent Q&A with Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) at Investorideas.com
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
About Sunshine Biopharma Inc. (OTCBB: SBFM)
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Research biotech stocks at the Investor Ideas Biotech stocks Directory
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
Last week the Company reported that it had completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results of the study showed that Adva-27a is significantly more effective at killing Multidrug Resistant Small Cell Lung Cancer cells than Etoposide, the current commonly used drug for this type of cancer. This is the second form of Multidrug Resistant Cancer that Adva-27a has shown effectiveness against. The first, which we had announced on July 11, 2011, was MCF-7/MDR Multidrug Resistant Breast Cancer.
Recent Q&A with Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) at Investorideas.comhttp://www.investorideas.com/CO/SBFM/news/2012/07021.asp
About Sunshine Biopharma Inc. (OTCBB: SBFM)
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Research biotech stocks at the Investor Ideas Biotech stocks Directory
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Published at Investorideas.com newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): ProfileDisclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Gold Stocks; Gold Bullion Development Corp. (TSX-V: GBB) files counter-claim against Genivar Inc.
VANCOUVER - July 4, 2012 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (TSXV: GBB, OTC PINK: GBBFF)
(the "Company" or "Gold Bullion") today announced that it had filed a
counter-claim against Genivar Inc. before the Superior Court of Quebec
(500-17-070970-127). In its counter-claim, Gold Bullion is claiming the
amount of $25,431,906.10 in damages from Genivar as a result of the
failure by the latter to properly perform its contractual obligations in
relation to the Granada and Castle Mines projects. In the same
proceeding, Gold Bullion also denied owing the amount of $783,652.06
which Genivar is claiming.
"No company ever wants to have to file a claim of this nature before the Courts," said Frank Basa , President and CEO of Gold Bullion Development Corp., "but we believe we had no other alternative in the matter. Genivar's failure to properly perform the work it was hired for in relation to the Granada and Castle Mines caused us substantial damages and the loss of at least one very interesting business opportunity."
The respective claims will now make their way through the Quebec Court system, where Gold Bullion firmly intends to assert its rights.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Quebec. Additional information on the company's Granada gold property is available by visiting their website at www.GoldBullionDevelopmentCorp.com and on SEDAR.com.
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
"No company ever wants to have to file a claim of this nature before the Courts," said Frank Basa , President and CEO of Gold Bullion Development Corp., "but we believe we had no other alternative in the matter. Genivar's failure to properly perform the work it was hired for in relation to the Granada and Castle Mines caused us substantial damages and the loss of at least one very interesting business opportunity."
The respective claims will now make their way through the Quebec Court system, where Gold Bullion firmly intends to assert its rights.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture-listed junior natural resource company focusing on the exploration and development of its Granada Property near Rouyn-Noranda, Quebec. Additional information on the company's Granada gold property is available by visiting their website at www.GoldBullionDevelopmentCorp.com and on SEDAR.com.
Frank J. Basa, P.Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Disclosure, Disclaimer/ Investorideas.com
is paid by GBB to publish news and distribute content through
Investordeas.com Newswire and its syndicated partners and blogs (five
hundred per month)Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.
Monday, July 02, 2012
Tech Stock Alert: Brightpoint (Nasdaq:CELL) Leads NASDAQ Top Gainers Spiking over 60% on Acquisition News
New York, NY - July 2, 2012 (Investorideas.com Newswire) Investor Ideas, www.InvestorIdeas.com, a global investor research portal for independent investors, issues a tech stock trading alert for Brightpoint, Inc. (Nasdaq:CELL),
gaining over 60% on acquisition news. The stock is trading at $8.84, up
$ 3.43 (63.31%) 12:35PM EDT on over 23 Million shares.
Ingram Micro Inc. (NYSE:IM) and Brightpoint, Inc. (Nasdaq:CELL) announced today they have entered into a definitive agreement under which, subject to customary closing conditions, Ingram Micro will acquire all of the outstanding shares of BrightPoint common stock for $9.00 per share in cash, a 66 percent premium to BrightPoint's closing stock price on June 29, 2012, and a 35 percent premium to the 90-day average trading price. The transaction is valued at approximately $840 million, including the value of approximately $190 million of BrightPoint's estimated debt (net of cash), as of June 30, 2012.
The Company also announced preliminary estimates on certain aspects of its financial results for the quarter ended June 30, 2012.
About Brightpoint, Inc.
Brightpoint, Inc. (Nasdaq:CELL) is a global leader in providing device lifecycle services to the wireless and high-tech industries. In 2011, BrightPoint handled more than 112 million wireless devices globally. BrightPoint's 5 key service areas - Plan, Market, Customize, Move, Recover, offer over 110 innovative services, such as distribution channel management, procurement, inventory management, reverse logistics and repair services, software loading, kitting and customized packaging, fulfillment, product customization, eBusiness solutions, and other outsourced services that integrate seamlessly with its customers' IT systems and operations. BrightPoint's effective and efficient platform allows its customers to benefit from rapidly deployed, flexible and cost effective solutions. BrightPoint has more than 4,000 employees, as well as a significant number of temporary staff, and a global footprint covering more than 35 countries, including 13 Latin American countries through its investment in Intcomex, Inc. In 2011, BrightPoint generated revenue of $5.2 billion, from customers in over 75 countries. BrightPoint provides distribution and customized services through over 100,000 points-of-sale and to over 25,000 B2B customers worldwide. website at www.BrightPoint.com
About Investorideas.com
InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Ingram Micro Inc. (NYSE:IM) and Brightpoint, Inc. (Nasdaq:CELL) announced today they have entered into a definitive agreement under which, subject to customary closing conditions, Ingram Micro will acquire all of the outstanding shares of BrightPoint common stock for $9.00 per share in cash, a 66 percent premium to BrightPoint's closing stock price on June 29, 2012, and a 35 percent premium to the 90-day average trading price. The transaction is valued at approximately $840 million, including the value of approximately $190 million of BrightPoint's estimated debt (net of cash), as of June 30, 2012.
The Company also announced preliminary estimates on certain aspects of its financial results for the quarter ended June 30, 2012.
About Brightpoint, Inc. Brightpoint, Inc. (Nasdaq:CELL) is a global leader in providing device lifecycle services to the wireless and high-tech industries. In 2011, BrightPoint handled more than 112 million wireless devices globally. BrightPoint's 5 key service areas - Plan, Market, Customize, Move, Recover, offer over 110 innovative services, such as distribution channel management, procurement, inventory management, reverse logistics and repair services, software loading, kitting and customized packaging, fulfillment, product customization, eBusiness solutions, and other outsourced services that integrate seamlessly with its customers' IT systems and operations. BrightPoint's effective and efficient platform allows its customers to benefit from rapidly deployed, flexible and cost effective solutions. BrightPoint has more than 4,000 employees, as well as a significant number of temporary staff, and a global footprint covering more than 35 countries, including 13 Latin American countries through its investment in Intcomex, Inc. In 2011, BrightPoint generated revenue of $5.2 billion, from customers in over 75 countries. BrightPoint provides distribution and customized services through over 100,000 points-of-sale and to over 25,000 B2B customers worldwide. website at www.BrightPoint.com
About Investorideas.com
InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB: SBFM) Discussing its Lead Compound - Adva-27a for Aggressive Forms of Cancer
New York, New York - July 2, 2012 - Investorideas.com, an investor
research portal specializing in sector research including biotech and
pharma stocks, issues an exclusive Q&A interview with Mr. Camille
Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM).Sunshine
Biopharma is a pharmaceutical company focused on the research,
development and commercialization of drugs for the treatment of various
forms of cancer. The Company’s lead compound, Adva-27a targets
aggressive forms of cancer.
Mr. Sebaaly also shares insight on Roche's (SIX: RO, ROG; OTCQX: RHHBY) Herceptin® cancer drug.
Interview:
Q: Investorideas.com staff
Can you give investors a brief background on your lead compound , Adva-27a, your proprietary technology behind it and how it targets aggressive forms of cancer?
A: Mr. Camille Sebaaly, CFO
Adva-27a is a small molecule which we designed and synthesized de novo. Patents covering Adva-27a and derivatives have been issued in the United States and Europe and are still pending in other places around the world. Adva-27a was designed it to specifically target multidrug resistant (or aggressive) types of cancer.
Q: Investorideas.com staff
The Company announced findings last week from the cytotoxicity study- can you give us some brief hi-lights and the significance of the results?
A: Mr. Camille Sebaaly, CFO
Last week we announced the results of our most recent studies in which we found that Adva-27a is remarkably capable of killing multidrug resistant small cell lung cancer. Small cell lung cancer is perhaps the most aggressive primary cancer. Sadly, the prognosis for a freshly diagnosed patient with small cell lung cancer is only a few months. As you know, we had announced back in July of last year that Adva-27a also kills multidrug resistant breast cancer cells. Similarly, the prognosis for multidrug resistant breast cancer patients is only a few months. We are delighted at the opportunity to offer both of these patient groups hope through our Adva-27a. As far we know, Adva-27a is the only drug anywhere in the world that can treat these patients.
Q: Investorideas.com staff
Can you discuss briefly the pharmacokinetics studies results announced in May?
A: Mr. Camille Sebaaly, CFO
The pharmacokinetic parameters of Adva-27a which we announced in May were excellent. Adva-27a has all the properties of a good pharmaceutical. For example, it reaches a very high initial plasma concentration, which means it starts working fast, and has an intermediates plasma half-life implying that it does not linger in the blood stream to cause severe side-effects and other complications.
Q: Investorideas.com staff
Can you give investors insight into the type of cancer Herceptin®, a drug marketed by Roche (SIX: RO, ROG; OTCQX: RHHBY) (the world's largest biotech company) targets and where you see Sunshine Biopharma filling the gap?
A: Mr. Camille Sebaaly, CFO
Herceptin® is an excellent drug and is very effective in treating Her2-Positive breast cancer patients. However, only about 25% of the breast cancer patients are Her2-Positive. For the remaining 75%, Herceptin® does not work. This is where our Adva-27a comes in. It is interesting to note that Herceptin® sales are in excess of $5 billion a year.
About Sunshine Biopharma Inc. (OTCBB: SBFM)
www.sunshinebiopharma.com
SBFM Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Research biotech stocks at the Investor Ideas Biotech stocks Directory
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Mr. Sebaaly also shares insight on Roche's (SIX: RO, ROG; OTCQX: RHHBY) Herceptin® cancer drug.
Interview:
Q: Investorideas.com staff
Can you give investors a brief background on your lead compound , Adva-27a, your proprietary technology behind it and how it targets aggressive forms of cancer?
A: Mr. Camille Sebaaly, CFO
Adva-27a is a small molecule which we designed and synthesized de novo. Patents covering Adva-27a and derivatives have been issued in the United States and Europe and are still pending in other places around the world. Adva-27a was designed it to specifically target multidrug resistant (or aggressive) types of cancer.
Q: Investorideas.com staff
The Company announced findings last week from the cytotoxicity study- can you give us some brief hi-lights and the significance of the results?
A: Mr. Camille Sebaaly, CFO
Last week we announced the results of our most recent studies in which we found that Adva-27a is remarkably capable of killing multidrug resistant small cell lung cancer. Small cell lung cancer is perhaps the most aggressive primary cancer. Sadly, the prognosis for a freshly diagnosed patient with small cell lung cancer is only a few months. As you know, we had announced back in July of last year that Adva-27a also kills multidrug resistant breast cancer cells. Similarly, the prognosis for multidrug resistant breast cancer patients is only a few months. We are delighted at the opportunity to offer both of these patient groups hope through our Adva-27a. As far we know, Adva-27a is the only drug anywhere in the world that can treat these patients.
Q: Investorideas.com staff
Can you discuss briefly the pharmacokinetics studies results announced in May?
A: Mr. Camille Sebaaly, CFO
The pharmacokinetic parameters of Adva-27a which we announced in May were excellent. Adva-27a has all the properties of a good pharmaceutical. For example, it reaches a very high initial plasma concentration, which means it starts working fast, and has an intermediates plasma half-life implying that it does not linger in the blood stream to cause severe side-effects and other complications.
Q: Investorideas.com staff
Can you give investors insight into the type of cancer Herceptin®, a drug marketed by Roche (SIX: RO, ROG; OTCQX: RHHBY) (the world's largest biotech company) targets and where you see Sunshine Biopharma filling the gap?
A: Mr. Camille Sebaaly, CFO
Herceptin® is an excellent drug and is very effective in treating Her2-Positive breast cancer patients. However, only about 25% of the breast cancer patients are Her2-Positive. For the remaining 75%, Herceptin® does not work. This is where our Adva-27a comes in. It is interesting to note that Herceptin® sales are in excess of $5 billion a year.
About Sunshine Biopharma Inc. (OTCBB: SBFM)
www.sunshinebiopharma.com
SBFM Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Research biotech stocks at the Investor Ideas Biotech stocks Directory
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Published at Investorideas.com newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): ProfileDisclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Friday, June 29, 2012
NASDAQ Morning Leader: Smith & Wesson (NASDAQ:SWHC) Trades up on Record Earnings
New York, NY- June 29, 2012 (www.Investorideas.com Newswire, www.homelanddefensestocks.com ) Investorideas.com, a leader in sector research for independent investors issues a trading alert for NASDAQ top percentage gainer this morning, Smith & Wesson Holding Corporation (NASDAQ:SWHC), trading at $8.05, up $1.16 or (16.84%) as of 10:15AM EDT on over 2.4 Million shares . The Company reported “Record Fourth Quarter and Full Year Fiscal 2012 Financial Results” in news yesterday .
Net sales from continuing operations for the fourth
quarter were a record $129.8 million, up 27.7% from the fourth quarter
last year. The increase was driven by strong sales of M&P™ polymer
pistols and M&P modern sporting rifles.
Hi-lights
- Record Fiscal Fourth Quarter 2012 Net Sales from Continuing Operations of $129.8 Million, Up 27.7% Year-Over-Year
- Record Fiscal Fourth Quarter 2012 Income from Continuing Operations of $17.8 Million or $0.27 per diluted share
- Record Annual Fiscal 2012 Income from Continuing Operations of $26.4 Million or $0.40 per diluted share
- Record Annual Units Produced
- Record Annual Cash Generated
- Company Issues Fiscal 2013 Financial Outlook
Smith
& Wesson Holding Corporation (NASDAQ Global Select: SWHC) is a
U.S.-based leader in firearm manufacturing and design, delivering a
broad portfolio of quality firearms, related products,
and training to the global military, law enforcement, and consumer
markets. The company's brands include Smith & Wesson®, M&P™ and
Thompson/Center Arms. Smith & Wesson facilities are located in Massachusetts and Maine. For more information on Smith & Wesson, call (800) 331-0852 or log on to www.smith-wesson.com.
About InvestorIdeas.com:
InvestorIdeas.com
is a leader in investor stock research by sector. Sectors we cover
include; water and renewable energy stocks, biotech stocks, mining and
gold stocks, energy stocks, natural gas stocks, tech, defense and security stocks, nanotech, China stocks and agriculture.
Get Free investor news and stock alerts at Investor Ideas
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Disclaimer:
Our sites do not make recommendations. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or
securities. We attempt to research thoroughly, but we offer no
guarantees as to the accuracy of information presented. All Information
relating to featured companies is sourced from public documents and/ or
the company and is not the opinion of our web sites. This site is
currently compensated by featured companies, news submissions and online
advertising. www.InvestorIdeas.com/About/
Thursday, June 28, 2012
Natural Gas Stocks Investor Alert: Progress Energy (TSX:PRQ) Spike over 70% on PETRONAS Deal
New York, NY - June 28, 2012 (Investorideas.com Newswire,
www.naturalgasstocks.com) Investorideas.com, a leader in sector stock
research for independent investors issues a trading snapshot for natural
gas stock Progress Energy Resources Corp. (TSX:PRQ), trading up at
$20.07, gaining $8.52 or (73.77%) 11:04AM EDT on over 28 Million shares
following news that it had entered into an agreement for the purchase
by PETRONAS Canada of all of Progress' outstanding common shares at a cash price of C$20.45 per share.
Highlights
Cash price of C$20.45 per Progress share Transaction has received the unanimous approval of Progress’ Board of Directors PETRONAS brings substantial investments in LNG infrastructure and access to world markets through established channels Canadian operations to remain based in Calgary for upstream with commercial office in Vancouver for LNG
About PETRONAS
PETRONAS is the national oil and gas company of Malaysia. Incorporated in 1974 the company, ranked among the most profitable among the Fortune Global 500 entities, is engaged in the oil, gas and petrochemicals industries with strategic business assets and interests in more than 30 countries. It is one of the world’s leading LNG companies and is fully involved in every value chain of the LNG business, from liquefaction and shipping to re-gasification and trading. Apart from its Malaysian production facility, currently one of the world’s largest, PETRONAS also owns interests in LNG assets in Australia and Egypt.
About Progress Energy
Progress is a Calgary, Canada-based Energy Company focused on exploration, development and production of large, unconventional natural gas resources in northeast British Columbia and northwest Alberta . Progress holds the largest acreage position in the Montney shale gas play. Throughout its history, Progress has a solid track record of growing reserves, production and the underlying value of the Company for its shareholders. Common shares of Progress are listed on the Toronto Stock Exchange under the symbol PRQ.
Research natural gas stocks at Investorideas.com directory
Research cleantech stocks at the renewable energy stocks directory
Sign up for the free investor news and stock alerts at Investorideas.com
Join Investor Ideas - Become a Member
Investorideas.com Members currently have 24/7 online access to exclusive subscriber-only 13 stock directories in leading sectors including natural gas, renewable energy, water, biotech, nanotech and more : http://www.investorideas.com/membership/
About www.InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com
800 665 0411
Highlights
Cash price of C$20.45 per Progress share Transaction has received the unanimous approval of Progress’ Board of Directors PETRONAS brings substantial investments in LNG infrastructure and access to world markets through established channels Canadian operations to remain based in Calgary for upstream with commercial office in Vancouver for LNG
About PETRONAS PETRONAS is the national oil and gas company of Malaysia. Incorporated in 1974 the company, ranked among the most profitable among the Fortune Global 500 entities, is engaged in the oil, gas and petrochemicals industries with strategic business assets and interests in more than 30 countries. It is one of the world’s leading LNG companies and is fully involved in every value chain of the LNG business, from liquefaction and shipping to re-gasification and trading. Apart from its Malaysian production facility, currently one of the world’s largest, PETRONAS also owns interests in LNG assets in Australia and Egypt.
About Progress Energy
Progress is a Calgary, Canada-based Energy Company focused on exploration, development and production of large, unconventional natural gas resources in northeast British Columbia and northwest Alberta . Progress holds the largest acreage position in the Montney shale gas play. Throughout its history, Progress has a solid track record of growing reserves, production and the underlying value of the Company for its shareholders. Common shares of Progress are listed on the Toronto Stock Exchange under the symbol PRQ.
Research natural gas stocks at Investorideas.com directory
Research cleantech stocks at the renewable energy stocks directory
Sign up for the free investor news and stock alerts at Investorideas.com
Join Investor Ideas - Become a Member
Investorideas.com Members currently have 24/7 online access to exclusive subscriber-only 13 stock directories in leading sectors including natural gas, renewable energy, water, biotech, nanotech and more : http://www.investorideas.com/membership/
About www.InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com
800 665 0411
Wednesday, June 27, 2012
Biotech Stock Alert; Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
SAN DIEGO - June 27, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
On June 12 th, I issued a detailed note referencing a landmark discovery that cancer-secreted exosomes seed the spread of metastasis in melanoma patients, and added that the Aethlon Hemopurifier®, which we have been advancing with promising results in the treatment of hepatitis c (HCV) infected individuals, has been validated in vitro to capture a variety of cancer-secreted exosomes, including those tested from melanoma patients.
Last week, we disclosed that the U.S. Patent and Trademark Office (USPTO) provided a Notice of Allowance for U.S. Patent Application No. 12/282152 entitled "Extracorporeal Removal of Microvesicular Particles," which provides us with broad rights to remove immune suppressive microvesicular particles, which include but are not limited to exosomes, from the circulation of treated patients.
Today, I am pleased to disclose that a paper authored by members of our Aethlon team, entitled, "Exosome Removal as a Therapeutic Adjuvant in Cancer" was published this morning in the Journal of Translational Medicine and is now accessible online at www.translational-medicine.com.
We believe the publication to be quite timely as cancer-secreted exosomes have recently emerged to become a vital therapeutic target as they play an instrumental role in promoting tumor progression by inducing programmed cell death of anti-cancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. The particles also seed the spread of tumor metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
All financial disclosures, anticipated revenue recognition amounts and other information related to the financial results and operations of the Company set forth above are unaudited and are subject to year-end audit adjustments and footnote disclosures.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs
On June 12 th, I issued a detailed note referencing a landmark discovery that cancer-secreted exosomes seed the spread of metastasis in melanoma patients, and added that the Aethlon Hemopurifier®, which we have been advancing with promising results in the treatment of hepatitis c (HCV) infected individuals, has been validated in vitro to capture a variety of cancer-secreted exosomes, including those tested from melanoma patients.
Last week, we disclosed that the U.S. Patent and Trademark Office (USPTO) provided a Notice of Allowance for U.S. Patent Application No. 12/282152 entitled "Extracorporeal Removal of Microvesicular Particles," which provides us with broad rights to remove immune suppressive microvesicular particles, which include but are not limited to exosomes, from the circulation of treated patients.
Today, I am pleased to disclose that a paper authored by members of our Aethlon team, entitled, "Exosome Removal as a Therapeutic Adjuvant in Cancer" was published this morning in the Journal of Translational Medicine and is now accessible online at www.translational-medicine.com.
We believe the publication to be quite timely as cancer-secreted exosomes have recently emerged to become a vital therapeutic target as they play an instrumental role in promoting tumor progression by inducing programmed cell death of anti-cancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. The particles also seed the spread of tumor metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
All financial disclosures, anticipated revenue recognition amounts and other information related to the financial results and operations of the Company set forth above are unaudited and are subject to year-end audit adjustments and footnote disclosures.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs
Subscribe to:
Posts (Atom)